Skip to main content
Clinical Trials/CTRI/2014/01/004276
CTRI/2014/01/004276
Recruiting
Phase 3

Role of PET/CT in assessment of metabolic response of neoadjuvant chemoradiotherapy in patients with carcinoma esophagus

All India Institute of Medical Sciences New Delhi0 sites50 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Health Condition 1: null- Carcinoma esophagus patients undergoing neoadjuvant chemoradiotherapy
Sponsor
All India Institute of Medical Sciences New Delhi
Enrollment
50
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
All India Institute of Medical Sciences New Delhi

Eligibility Criteria

Inclusion Criteria

  • 1\.Age \< 65 years
  • 2\.Squamous cell carcinoma
  • 3\.Good performance status (Eastern Cooperative Oncology Group \[ECOG] grades 0, 1 and 2\)
  • 4\. Contrast enhanced computerized tomographic (CECT) scan suggesting a potentially resectable lesion. The features of resectability assessed on CECT scan will include \- no evidence of infiltration of mediastinal structures such as the aorta (angle of contact \<90°, no obliteration of the triangular fat space between the esophagus, aorta, and spine), and pericardium, and no evidence of tracheobronchial fistula or tumor extension into the airway lumen.
  • 5\.No evidence of distant metastasis on CECT.

Exclusion Criteria

  • 1\.Comorbid conditions which would preclude esophagectomy
  • Poor performance status (ECOG \> 2\)
  • American Society of Anesthesiologists class IV
  • 2\.Metastatic disease detected on evaluation
  • 3\.Involvement of mediastinal structures
  • 4\.Carcinoma involving cervical esophagus
  • 5\.Previous radiotherapy or chemotherapy

Outcomes

Primary Outcomes

Not specified

Similar Trials